Effect of tazobactam/piperacillin on intestinal bacterial flora - Studies in the pediatric field

Satoshi Iwata, Isamu Kamimaki, Eiichi Isohata, Yoshiaki Kin, Takao Yokota, Yutaka Kusumoto, Yoshitaka Sato, Hironobu Akita, Seiichiro Nanri, Tadao Oikawa, Keisuke Sunagawa

Research output: Contribution to journalArticle

Abstract

Tazobactam/piperacillin (TAZ/PIPC), a new injectable combination antibiotic consisting of tazobactam (TAZ), a new β-lactamase inhibitor, and piperacillin (PIPC), an injectable penicillin, in a ratio of 1: 4 (potency) was studied with regard to its effect on the intestinal flora of pediatric patients. Five children with infections (2 boys and 3 girls; ages: 4 months to 9 years 10 months; body weights 8.14-28.0 kg) were given TAZ/PIPC at 43-53.6 mg/kg 4 times daily for 5-15 days. Before, during and after administration, fecal samples were collected and bacterial contents per gram of feces were assessed and viable cells counted for each bacterial species. At the same time, fecal levels of TAZ and PIPC, β-lactamase activity and contents of Clostridium difficle D-1 antigen were also determined. With regards to changes in fecal bacterial flora during administration of TAZ/PIPC, slight individual differences were seen. A decreasing tendency was seen in Enterobacteriaceae among major aerobes in feces. The cell count of this species of bacteria decreased remarkably, falling below the detectable limit in 3 of 5 cases. The cell count of Enterococcus also fell below the detectable limit in 3 of 5 cases. In the 2 remaining cases, changes in bacteria occurred within the genera of the bacterial species examined. As a result, the total cell count of aerobes decreased remarkably in 1 case and slightly in 1 other case. Among anaerobes in feces, Bifidobacterium, Eubacterium and Bacteroides, which had been prevalent, showed a remarkable decrease in cell count during treatment. In 3 cases, the total cell count of anaerobes decreased remarkably. In all 3 of these cases the patients were infants. An increasing tendency was seen in glucose-nonfermentative gram-negative rods, fungi and Bacillus in 1, 4 and 4 cases, respectively, during treatment. In 2 infants in whom remarkable decreases were seen in Enterobacteriaceae, Enterococcus and the main fecal anaerobes, diarrhea was observed, and Candida became the most predominant organism during treatment. C. difficile and C. difficile D-1 antigen were isolated in 1 and 2 cases, respectively, and no relation was found between changes in these counts and fecal characteristics. In 2 cases, TAZ was detected in feces during administration and the fecal concentration ranged from 27.4 to 41.8 μg/g. On the other hand, PIPC was detected in feces during treatment in 3 infants in whom marked changes were seen in the intestinal flora. These cases had fecal concentrations of 34.7 to 238 μg/g. Before treatment, β-lactamase activity was positive in 4 cases. In 3 of these cases, conversion to negativity was obtained during treatment. From these results, TAZ/PIPC is considered to have a marked in fluence on the intestinal flora in childeren. Caution should thus be exercised as the development of diarrhea, along with changes in gastrointestinal bacteria, may occus during the use of TAZ/PIPC.

Original languageEnglish
Pages (from-to)428-435
Number of pages8
JournalJapanese Journal of Chemotherapy
Volume44
Issue number6
Publication statusPublished - 1996
Externally publishedYes

Fingerprint

Feces
Pediatrics
Cell Count
Enterococcus
Enterobacteriaceae
Bacteria
Diarrhea
Therapeutics
Accidental Falls
Eubacterium
Antigens
Piperacillin
Injections
Bacteroides
Bifidobacterium
Clostridium
Candida
Individuality
Penicillins
Bacillus

ASJC Scopus subject areas

  • Pharmacology

Cite this

Iwata, S., Kamimaki, I., Isohata, E., Kin, Y., Yokota, T., Kusumoto, Y., ... Sunagawa, K. (1996). Effect of tazobactam/piperacillin on intestinal bacterial flora - Studies in the pediatric field. Japanese Journal of Chemotherapy, 44(6), 428-435.

Effect of tazobactam/piperacillin on intestinal bacterial flora - Studies in the pediatric field. / Iwata, Satoshi; Kamimaki, Isamu; Isohata, Eiichi; Kin, Yoshiaki; Yokota, Takao; Kusumoto, Yutaka; Sato, Yoshitaka; Akita, Hironobu; Nanri, Seiichiro; Oikawa, Tadao; Sunagawa, Keisuke.

In: Japanese Journal of Chemotherapy, Vol. 44, No. 6, 1996, p. 428-435.

Research output: Contribution to journalArticle

Iwata, S, Kamimaki, I, Isohata, E, Kin, Y, Yokota, T, Kusumoto, Y, Sato, Y, Akita, H, Nanri, S, Oikawa, T & Sunagawa, K 1996, 'Effect of tazobactam/piperacillin on intestinal bacterial flora - Studies in the pediatric field', Japanese Journal of Chemotherapy, vol. 44, no. 6, pp. 428-435.
Iwata S, Kamimaki I, Isohata E, Kin Y, Yokota T, Kusumoto Y et al. Effect of tazobactam/piperacillin on intestinal bacterial flora - Studies in the pediatric field. Japanese Journal of Chemotherapy. 1996;44(6):428-435.
Iwata, Satoshi ; Kamimaki, Isamu ; Isohata, Eiichi ; Kin, Yoshiaki ; Yokota, Takao ; Kusumoto, Yutaka ; Sato, Yoshitaka ; Akita, Hironobu ; Nanri, Seiichiro ; Oikawa, Tadao ; Sunagawa, Keisuke. / Effect of tazobactam/piperacillin on intestinal bacterial flora - Studies in the pediatric field. In: Japanese Journal of Chemotherapy. 1996 ; Vol. 44, No. 6. pp. 428-435.
@article{9473bd7b814a45c9878bd7225baeeb8a,
title = "Effect of tazobactam/piperacillin on intestinal bacterial flora - Studies in the pediatric field",
abstract = "Tazobactam/piperacillin (TAZ/PIPC), a new injectable combination antibiotic consisting of tazobactam (TAZ), a new β-lactamase inhibitor, and piperacillin (PIPC), an injectable penicillin, in a ratio of 1: 4 (potency) was studied with regard to its effect on the intestinal flora of pediatric patients. Five children with infections (2 boys and 3 girls; ages: 4 months to 9 years 10 months; body weights 8.14-28.0 kg) were given TAZ/PIPC at 43-53.6 mg/kg 4 times daily for 5-15 days. Before, during and after administration, fecal samples were collected and bacterial contents per gram of feces were assessed and viable cells counted for each bacterial species. At the same time, fecal levels of TAZ and PIPC, β-lactamase activity and contents of Clostridium difficle D-1 antigen were also determined. With regards to changes in fecal bacterial flora during administration of TAZ/PIPC, slight individual differences were seen. A decreasing tendency was seen in Enterobacteriaceae among major aerobes in feces. The cell count of this species of bacteria decreased remarkably, falling below the detectable limit in 3 of 5 cases. The cell count of Enterococcus also fell below the detectable limit in 3 of 5 cases. In the 2 remaining cases, changes in bacteria occurred within the genera of the bacterial species examined. As a result, the total cell count of aerobes decreased remarkably in 1 case and slightly in 1 other case. Among anaerobes in feces, Bifidobacterium, Eubacterium and Bacteroides, which had been prevalent, showed a remarkable decrease in cell count during treatment. In 3 cases, the total cell count of anaerobes decreased remarkably. In all 3 of these cases the patients were infants. An increasing tendency was seen in glucose-nonfermentative gram-negative rods, fungi and Bacillus in 1, 4 and 4 cases, respectively, during treatment. In 2 infants in whom remarkable decreases were seen in Enterobacteriaceae, Enterococcus and the main fecal anaerobes, diarrhea was observed, and Candida became the most predominant organism during treatment. C. difficile and C. difficile D-1 antigen were isolated in 1 and 2 cases, respectively, and no relation was found between changes in these counts and fecal characteristics. In 2 cases, TAZ was detected in feces during administration and the fecal concentration ranged from 27.4 to 41.8 μg/g. On the other hand, PIPC was detected in feces during treatment in 3 infants in whom marked changes were seen in the intestinal flora. These cases had fecal concentrations of 34.7 to 238 μg/g. Before treatment, β-lactamase activity was positive in 4 cases. In 3 of these cases, conversion to negativity was obtained during treatment. From these results, TAZ/PIPC is considered to have a marked in fluence on the intestinal flora in childeren. Caution should thus be exercised as the development of diarrhea, along with changes in gastrointestinal bacteria, may occus during the use of TAZ/PIPC.",
author = "Satoshi Iwata and Isamu Kamimaki and Eiichi Isohata and Yoshiaki Kin and Takao Yokota and Yutaka Kusumoto and Yoshitaka Sato and Hironobu Akita and Seiichiro Nanri and Tadao Oikawa and Keisuke Sunagawa",
year = "1996",
language = "English",
volume = "44",
pages = "428--435",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "6",

}

TY - JOUR

T1 - Effect of tazobactam/piperacillin on intestinal bacterial flora - Studies in the pediatric field

AU - Iwata, Satoshi

AU - Kamimaki, Isamu

AU - Isohata, Eiichi

AU - Kin, Yoshiaki

AU - Yokota, Takao

AU - Kusumoto, Yutaka

AU - Sato, Yoshitaka

AU - Akita, Hironobu

AU - Nanri, Seiichiro

AU - Oikawa, Tadao

AU - Sunagawa, Keisuke

PY - 1996

Y1 - 1996

N2 - Tazobactam/piperacillin (TAZ/PIPC), a new injectable combination antibiotic consisting of tazobactam (TAZ), a new β-lactamase inhibitor, and piperacillin (PIPC), an injectable penicillin, in a ratio of 1: 4 (potency) was studied with regard to its effect on the intestinal flora of pediatric patients. Five children with infections (2 boys and 3 girls; ages: 4 months to 9 years 10 months; body weights 8.14-28.0 kg) were given TAZ/PIPC at 43-53.6 mg/kg 4 times daily for 5-15 days. Before, during and after administration, fecal samples were collected and bacterial contents per gram of feces were assessed and viable cells counted for each bacterial species. At the same time, fecal levels of TAZ and PIPC, β-lactamase activity and contents of Clostridium difficle D-1 antigen were also determined. With regards to changes in fecal bacterial flora during administration of TAZ/PIPC, slight individual differences were seen. A decreasing tendency was seen in Enterobacteriaceae among major aerobes in feces. The cell count of this species of bacteria decreased remarkably, falling below the detectable limit in 3 of 5 cases. The cell count of Enterococcus also fell below the detectable limit in 3 of 5 cases. In the 2 remaining cases, changes in bacteria occurred within the genera of the bacterial species examined. As a result, the total cell count of aerobes decreased remarkably in 1 case and slightly in 1 other case. Among anaerobes in feces, Bifidobacterium, Eubacterium and Bacteroides, which had been prevalent, showed a remarkable decrease in cell count during treatment. In 3 cases, the total cell count of anaerobes decreased remarkably. In all 3 of these cases the patients were infants. An increasing tendency was seen in glucose-nonfermentative gram-negative rods, fungi and Bacillus in 1, 4 and 4 cases, respectively, during treatment. In 2 infants in whom remarkable decreases were seen in Enterobacteriaceae, Enterococcus and the main fecal anaerobes, diarrhea was observed, and Candida became the most predominant organism during treatment. C. difficile and C. difficile D-1 antigen were isolated in 1 and 2 cases, respectively, and no relation was found between changes in these counts and fecal characteristics. In 2 cases, TAZ was detected in feces during administration and the fecal concentration ranged from 27.4 to 41.8 μg/g. On the other hand, PIPC was detected in feces during treatment in 3 infants in whom marked changes were seen in the intestinal flora. These cases had fecal concentrations of 34.7 to 238 μg/g. Before treatment, β-lactamase activity was positive in 4 cases. In 3 of these cases, conversion to negativity was obtained during treatment. From these results, TAZ/PIPC is considered to have a marked in fluence on the intestinal flora in childeren. Caution should thus be exercised as the development of diarrhea, along with changes in gastrointestinal bacteria, may occus during the use of TAZ/PIPC.

AB - Tazobactam/piperacillin (TAZ/PIPC), a new injectable combination antibiotic consisting of tazobactam (TAZ), a new β-lactamase inhibitor, and piperacillin (PIPC), an injectable penicillin, in a ratio of 1: 4 (potency) was studied with regard to its effect on the intestinal flora of pediatric patients. Five children with infections (2 boys and 3 girls; ages: 4 months to 9 years 10 months; body weights 8.14-28.0 kg) were given TAZ/PIPC at 43-53.6 mg/kg 4 times daily for 5-15 days. Before, during and after administration, fecal samples were collected and bacterial contents per gram of feces were assessed and viable cells counted for each bacterial species. At the same time, fecal levels of TAZ and PIPC, β-lactamase activity and contents of Clostridium difficle D-1 antigen were also determined. With regards to changes in fecal bacterial flora during administration of TAZ/PIPC, slight individual differences were seen. A decreasing tendency was seen in Enterobacteriaceae among major aerobes in feces. The cell count of this species of bacteria decreased remarkably, falling below the detectable limit in 3 of 5 cases. The cell count of Enterococcus also fell below the detectable limit in 3 of 5 cases. In the 2 remaining cases, changes in bacteria occurred within the genera of the bacterial species examined. As a result, the total cell count of aerobes decreased remarkably in 1 case and slightly in 1 other case. Among anaerobes in feces, Bifidobacterium, Eubacterium and Bacteroides, which had been prevalent, showed a remarkable decrease in cell count during treatment. In 3 cases, the total cell count of anaerobes decreased remarkably. In all 3 of these cases the patients were infants. An increasing tendency was seen in glucose-nonfermentative gram-negative rods, fungi and Bacillus in 1, 4 and 4 cases, respectively, during treatment. In 2 infants in whom remarkable decreases were seen in Enterobacteriaceae, Enterococcus and the main fecal anaerobes, diarrhea was observed, and Candida became the most predominant organism during treatment. C. difficile and C. difficile D-1 antigen were isolated in 1 and 2 cases, respectively, and no relation was found between changes in these counts and fecal characteristics. In 2 cases, TAZ was detected in feces during administration and the fecal concentration ranged from 27.4 to 41.8 μg/g. On the other hand, PIPC was detected in feces during treatment in 3 infants in whom marked changes were seen in the intestinal flora. These cases had fecal concentrations of 34.7 to 238 μg/g. Before treatment, β-lactamase activity was positive in 4 cases. In 3 of these cases, conversion to negativity was obtained during treatment. From these results, TAZ/PIPC is considered to have a marked in fluence on the intestinal flora in childeren. Caution should thus be exercised as the development of diarrhea, along with changes in gastrointestinal bacteria, may occus during the use of TAZ/PIPC.

UR - http://www.scopus.com/inward/record.url?scp=3042896383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042896383&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:3042896383

VL - 44

SP - 428

EP - 435

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - 6

ER -